Interestingly, a co-injection of apoA-I and CIGB-258 resulted in the lowest levels of TC and TG: 45% and 65% lower than those of the CML+PBS group, respectively, suggesting that a combination of apoA-I and CIGB-258 had higher lipid-lowering activity. Here, APOA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.